Related Experiment Video
Updated: Feb 14, 2026
Isolation of Cancer Stem Cells From Human Prostate Cancer Samples
Published on: March 14, 2014
Integrin Inhibitors in Prostate Cancer
Maylein C Juan-Rivera1,2, Magaly Martínez-Ferrer3,4
1Department of Pharmaceutical Sciences, School of Pharmacy, University of Puerto Rico, Medical Sciences Campus, San Juan, PR 00936, USA. maylein.juan@upr.edu.
Abstract:
Prostate cancer (PCa) is the most frequently diagnosed cancer and the third highest cause of cancer-related deaths in men in the U.S. The development of chemotherapeutic agents that can bind PCa tumor cells with high specificity is critical in order to increase treatment effectiveness. Integrin receptors and their corresponding ligands have different expression patterns in PCa cells. They have been identified as promising targets to inhibit pathways involved in PCa progression. Currently, several compounds have proven to target specific integrins and their subunits in PCa cells. In this article, we review the role of integrins inhibitors in PCa and their potential as therapeutic targets for PCa treatments. We have discussed the following: natural compounds, monoclonal antibodies, statins, campothecins analog, aptamers, d-aminoacid, and snake venom. Recent studies have shown that their mechanisms of action result in decrease cell migration, cell invasion, cell proliferation, and metastasis of PCa cells.
Insights
Integrin inhibitors show promise for treating prostate cancer (PCa) by targeting tumor cells. These agents reduce cancer cell migration, invasion, proliferation, and metastasis, offering new therapeutic avenues.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Prostate cancer (PCa) is a leading cause of cancer-related deaths in men.
- Targeting PCa cells with high specificity is crucial for effective chemotherapy.
- Integrin receptors are differentially expressed in PCa cells and are key regulators of cancer progression.
Purpose of the Study:
- To review the role of integrin inhibitors in prostate cancer.
- To explore the potential of integrin inhibitors as therapeutic targets for PCa.
- To summarize various classes of integrin inhibitors and their mechanisms.
Main Methods:
- Literature review of studies on integrin inhibitors in prostate cancer.
- Analysis of different classes of compounds targeting integrins: natural compounds, monoclonal antibodies, statins, campothecin analogs, aptamers, d-aminoacids, and snake venom.
- Examination of the impact of these inhibitors on PCa cell behavior.
Main Results:
- Integrin inhibitors demonstrate potential for specific targeting of PCa cells.
- Various classes of compounds have been identified that inhibit specific integrins and their subunits.
- Inhibitor mechanisms lead to decreased PCa cell migration, invasion, proliferation, and metastasis.
Conclusions:
- Integrin inhibitors represent a promising therapeutic strategy for prostate cancer.
- Targeting integrins offers a means to disrupt critical pathways in PCa progression.
- Further research into integrin-targeted therapies could significantly improve PCa treatment outcomes.
Related Concept Videos
01:10Integrins
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
01:15Activation of Integrins
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
01:52Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
01:23Dipeptidyl Peptidase 4 Inhibitors
01:25Antihypertensive Drugs: Direct Renin Inhibitors
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...